UM Calabresi Clinical Oncology Research Career Development Award

UM Calabresi 临床肿瘤学研究职业发展奖

• 批准号: 10647023
• 负责人: Alan Pollack
• 金额: $ 72.04万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-29 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10647023
• 关键词: Advocate; Cell Transplantation; Childhood; Clinical Management; Clinical Oncology; Clinical Oncology Supplement (K12); Clinical Sciences; Clinical Trials; Collaborations; Communities; Comprehensive Cancer Center; Critiques; Development; Doctor of Philosophy; Educational Curriculum; Faculty; Faculty Recruitment; Feedback; Fellowship; Florida; Foundations; Grant; Gynecologic Oncology; Head and neck structure; Hematology; Joints; K-Series Research Career Programs; Link; Liquid substance; Malignant Neoplasms; Master of Science; Medical; Medical Oncologist; Medical Oncology; Mentored Clinical Scientist Development Program; Mentors; Mentorship; Oncology; Operative Surgical Procedures; Patients; Phase; Physicians; Population; Population Sciences; Process; Radiation; Radiation Oncologist; Radiation Oncology; Research; Residencies; Resources; Running; Scholarship; Scientist; Solid Neoplasm; Standardization; Structure; Students; Surgical Oncology; Training; Translational Research; Universities; Urology; cancer health disparity; design; inter-institutional; medical specialties; oncology program; programs; recruit; tumor; urologic

PROJECT SUMMARY/ABSTRACT The University of Miami (UM) Sylvester Comprehensive Cancer Center (SCCC) K12 Calabresi Clinical Oncology Research Career Development program is designed to formalize a structured path to independent translational science that, at the core, is a strong foundation for clinical trial development and implementation that is intended to culminate in impactful changes in oncology patient management. Over the initial period of the grant, the SCCC achieved NCI designation and has committed significant resources to building and sustaining robust academic physician faculty recruitment and mentorship programs that are tied to strategic enhancement of the candidate pool for the K12 physician-scientist program. Candidate physician-scientists are recruited from all cancer related specialties. Department and Division chiefs at UM have promoted the program to incoming faculty completing their fellowships and residencies, and existing junior faculty within 5 years of completion of fellowship training. Scholars include those who recently completed postgraduate training in a subspecialty oncology program: pediatric, urologic, radiation, surgical, hematology (liquid tumors), medical (solid tumors), cell transplant, head and neck, ophthalmologic, gynecologic oncology. Of the 10 scholars who have entered, 4 are from hematology, 2 are from medical oncology, and 1 each are from surgical oncology, cell transplantation, urology, and radiation oncology. The PI of the K12 program is a radiation oncologist physician-scientist who has been the PI of phase I, II, and III trials and mentored numerous students, trainees, and faculty in translational research and clinical trial advancement. He organizes the K12 Design and Management of Clinical Trials course (CTC), which serves as a cornerstone of the curriculum. The K12 CTC has evolved into an inter-institutional course designed to enhance exposure of and recruitment into the K12 Program. There are two Associate Directors including (i) a medical oncologist (Jaime Merchan, MD) who leads the SCCC Phase I Program (the only such program in South Florida) and who oversees the homework portion of the CTC, wherein scholars and other invited faculty and fellows have their clinical trial concepts developed and critiqued; and (ii) a population scientist (Erin Kobetz, PhD, MPH) who is Associate Director of Population Sciences and Cancer Disparity in SCCC, as well as Vice Provost for Research and Scholarship for UM. Dr. Kobetz oversees the link between the scholars and community/patient advocates. The Internal and External Advisory, Executive, and Curriculum Committees provide feedback and are attuned to the need to have a diverse group of applicants to choose from. Based on feedback from the committees and scholars, revisions are being made to the core curriculum and Master of Science program run in collaboration with the UM Clinical and Translational Science Institute (CTSI). The collaboration with the CTSI KL2 program at UM has been formalized with a joint SCCC K12 and CTSI KL2 application process and standardized review criteria. As the CTSI KL2 transitions to a K12, we are working together through cross- committee participation to optimize these complementary and independent programs.

项目总结/摘要 迈阿密大学（UM）西尔维斯特综合癌症中心（SCCC）K12 Calabresi临床肿瘤学 研究职业发展计划旨在正式确定一个结构化的路径，以独立的翻译 核心科学是临床试验开发和实施的坚实基础， 最终在肿瘤患者管理方面产生有影响力的变化。在赠款的最初阶段，SCCC 获得了NCI的称号，并投入了大量资源，以建立和维持强大的学术 与候选人的战略性增强有关的医生教师招聘和导师计划 K12物理学家科学家项目的资金池候选医生-科学家从所有与癌症相关的 特产部门和部门负责人在UM已推动该计划，以新的教师完成 他们的奖学金和住院医师，以及现有的初级教师在5年内完成奖学金培训。 学者包括那些谁最近完成了研究生培训的亚专业肿瘤学计划： 儿科、泌尿科、放射科、外科、血液学（液体肿瘤）、内科（实体肿瘤）、细胞移植、头部 以及颈部、眼科、妇科肿瘤学。在10位入选的学者中，有4位来自血液学， 2名来自内科肿瘤科，1名来自外科肿瘤科、细胞移植科、泌尿科和放射科 肿瘤学K12项目的PI是一名放射肿瘤学家、内科医生兼科学家， I，II和III试验，并指导了许多学生，学员和教师在转化研究和临床 审判进展。他组织了K12临床试验设计和管理课程（CTC）， 作为课程的基石。K12 CTC已经发展成为一个机构间课程， 加强K12计划的曝光和招募。有两名副主任，包括（i）一名 医学肿瘤学家（Jaime Merchan，MD）领导SCCC I期项目（南加州唯一的此类项目）。 佛罗里达）和谁监督家庭作业部分的反恐委员会，其中学者和其他应邀教师和 研究员开发和评论了他们的临床试验概念;以及（ii）人口科学家（Erin Kobetz，PhD， 他是SCCC人口科学和癌症差异副主任，以及副教务长 研究和奖学金。Kobetz博士监督学者和社区/患者之间的联系 律师内部和外部咨询，执行和课程委员会提供反馈， 都适应了需要有一个多样化的申请人群体进行选择。根据来自 委员会和学者，修订正在进行的核心课程和科学硕士课程运行 临床和转化科学研究所（CTSI）。与CTSI的合作 UM的KL 2计划已通过联合SCCC K12和CTSI KL 2申请流程正式确定， 标准化的审查标准。随着CTSI KL 2过渡到K12，我们正在通过交叉合作， 委员会的参与，以优化这些互补和独立的方案。

项目成果

Relevance of sentinel lymph node biopsy for thick melanoma in the era of immunotherapy.

免疫治疗时代前哨淋巴结活检与厚黑色素瘤的相关性。

• DOI: 10.1016/j.suronc.2020.08.032
• 发表时间: 2020
• 期刊: Surgical oncology
• 作者: Picado,Omar;Ryon,EmilyL;Möller,MeckerG;Goel,Neha;Kesmodel,SusanB
• 通讯作者: Kesmodel,SusanB

Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.

• DOI: 10.1158/1078-0432.ccr-20-4054
• 发表时间: 2021-04-01
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Tayari MM;Santos HGD;Kwon D;Bradley TJ;Thomassen A;Chen C;Dinh Y;Perez A;Zelent A;Morey L;Cimmino L;Shiekhattar R;Swords RT;Watts JM
• 通讯作者: Watts JM

Infectious and Noninfectious Corneal Ulcers in Ocular Graft-Versus-Host Disease: Epidemiology, Clinical Characteristics, and Outcomes.

眼移植物抗宿主病中的感染性和非感染性角膜溃疡：流行病学、临床特征和结果。

• DOI: 10.1016/j.ajo.2023.09.018
• 发表时间: 2024
• 期刊: American journal of ophthalmology
• 影响因子: 4.2
• 作者: Sepulveda-Beltran,PaulaA;Carletti,Piero;Banda,Victor;Mulpuri,Lakshman;Levine,Harry;Amescua,Guillermo;Wang,TrentP;Galor,Anat;Tonk,Rahul
• 通讯作者: Tonk,Rahul

Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis.

• DOI: 10.1016/j.hpb.2020.11.1150
• 发表时间: 2021-06
• 期刊: HPB : the official journal of the International Hepato Pancreato Biliary Association
• 作者: Kronenfeld JP;Ryon EL;Goldberg D;Lee RM;Yopp A;Wang A;Lee AY;Luu S;Hsu C;Silberfein E;Russell MC;Merchant NB;Goel N
• 通讯作者: Goel N

Advantages of Radiation Therapy Simulation with 0.35 Tesla Magnetic Resonance Imaging for Stereotactic Ablation of Spinal Metastases.

0.35 特斯拉磁共振成像放射治疗模拟用于脊柱转移瘤立体定向消融的优势。

• DOI: 10.1016/j.prro.2019.10.018
• 发表时间: 2020
• 期刊: Practical radiation oncology
• 影响因子: 3.3
• 作者: Spieler,Benjamin;Samuels,StuartE;Llorente,Ricardo;Yechieli,Raphael;Ford,JohnChetley;Mellon,EricA
• 通讯作者: Mellon,EricA